Acurx Pharmaceuticals Announces Presentation of Ibezapolosta

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results from the ibezapolstat Phase 2 clinical...

Related Keywords

United States , Barcelona , Comunidad Autonoma De Cataluna , Spain , Switzerland , America , Kevin Garey , Eugenie Basseres , Davidp Luci , Acurx Pharmaceuticals Announces Presentation Of Ibezapolostat Phase , Nasdaq , University Of Houston College Pharmacy , Exchange Commission , Acurx Pharmaceuticals Inc , Global European Society Of Clinical Microbiology , Infectious Diseases Society Of America , Prnewswire Acurx Pharmaceuticals Inc , Data Monitoring Committee , Research Scientist , Trial Oversight Committee , Exchange Commission On Form , Acurx Pharmaceuticals , Company Ph , Society Or Healthcare Epidemiology Of America , Drug Administration , Company Scientific Advisory Board , European Society Of Clinical Microbiology , Pharmaceuticals Announces Presentation , Ibezapolostat Phase , Trial Results , European Society , Clinical Microbiology , Infectious Diseases , Houston College , Principal Investigator , Acurx Scientific Advisory Board , Double Blind Study , Ibezapolstat Compared , Executive Committee , Ibezapolstat Phase , Scientific Advisory Board , Clinical Cure , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Fast Track Designated , Gram Positive Selective Spectrum , Qualified Infectious Disease Product , Generating New Antibiotic Incentives Now , Clinical Practice Guidelines , Infectious Diseases Society , Healthcare Epidemiology , New England Journal , Bile Acid , Private Securities Litigation Reform Act ,